This compound is a salt-like pharmaceutical intermediate, consisting of a triethylamine salt of a modified guanosine diphosphate derivative. It is primarily used in research and pharmaceutical manufacturing contexts.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 2089461-52-7
((2R,3R,4R,5R)-5-(2-Amino-7-methyl-6-oxo-3,6-dihydro-9H-purin-7-ium-9-yl)-3-hydroxy-4-methoxytetrahydrofuran-2-yl)methyl hydrogen phosphate
RNA modification intermediate
2-(3-(4-Bromo-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
pharmaceutical intermediate
2-[[3,4-Dihydro-3-methyl-2,4-dioxo-6-[(3R)-3-piperidinylamino]-1(2H)-pyrimidinyl]methyl]-benzonitrile
Alogliptin impurity reference standard
8-Chloro-6-fluoroquinazoline-2,4-diol
Pharmaceutical intermediate for quinazoline derivatives
1-(bromomethyl)-1-(trifluoromethyl)cyclopentane
Pharmaceutical intermediate compound
7-methylguanosine 5'-(trihydrogen diphosphate)
Pharmaceutical intermediate for nucleotide analogs
[(2R,3S,4R,5R)-5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-4-hydroxy-3-methoxyoxolan-2-yl]methyl phosphono phosphate;N,N-diethylethanamine
OJSWUEWFFWZWMU-YCSZXMBFSA-N
CCN(CC)CC.CN1C=[N+](C2=C1C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)(O)O)OC)O